Floatz logo

m3814

Ovarian Undifferentiated Carcinoma

National Cancer Institute (NCI)Phase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

9 Active assets in the Ovarian Undifferentiated Carcinoma cohort.

Asset / SponsorPhaseRating
(+)-VINCRISTINE
National Cancer Institute (NCI)
Phase 3BBB
Irinotecan
National Cancer Institute (NCI)
Phase 3BBB
Carboplatin
National Cancer Institute (NCI)
Phase 3BBB
Inno-206
National Cancer Institute (NCI)
Phase 3BB
Cediranib
National Cancer Institute (NCI)
Phase 3BB

View all 17 →

Same molecule, other indications

m3814 is also rated in:

Advanced Solid TumorsDormant
CCC
Indicative ·
52 / 100
View asset →
Unresectable Malignant Solid NeoplasmDormant
CCC
Indicative ·
50 / 100
View asset →
Locally Advanced Unresectable Gallbladder CarcinomaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →